Rare cancer gets new treatment

Country

United States

A new epigenetic medicine has been approved in the US to treat epithelioid sarcoma, a rare sub-type of soft tissue sarcoma that affects young adults. The drug, Tazverik (tazemetostat), is a small molecule inhibitor of EZH2 methyltransferase which regulates gene expression. By blocking the activity of EZH2, the drug is expected to keep cancer cells from growing. The Food and Drug Administration announced the authorisation on 23 January.